| ²é¿´: 1130 | »Ø¸´: 4 | ||
cclz110Òø³æ (СÓÐÃûÆø)
|
[ÇóÖú]
Á½¸öµ¥´ÊµÄ·Ò룬ÓÐÓï¾³
|
|
Product means any pharmaceutical composition, in any dosage form, formulation,improvement or mode of administration, that comprises or incorporates the small molecule protein tyrosine kinase inhibitor designated as AL3810 (INN lucitanib), its pharmaceutically acceptable salts, esters, ethers, isomers, mixtures of isomers, complexes or derivatives or N-oxides. ²úÆ·ÊÇÖ¸ÈκÎÒ©Îï×éºÏÎÔÚÈκμÁÐÍ¡¢Åä·½¡¢¸ÄÉÆ»ò¸øÒ©·½Ê½ÖУ¬º¬Óлò²ÉÓÃС·Ö×Óµ°°×ÀÒ°±ËἤøÒÖÖÆ¼ÁAL3810£¨INN lucitanib£©£¬¼°ÆäҩѧÉϿɽÓÊܵÄÑΣ¬õ¥£¬ÃÑ£¬Òì¹¹Ì壬Òì¹¹Ìå»ìºÏÎ¸´ºÏÎï»òÑÜÉúÎï»òN-Ñõ»¯Îï¡£ µÚÒ»¸ö£¬ improvement or mode of administration,ÖеÄimprovementÔõô·Òë µÚ¶þ¸ö£¬complexes or derivatives or N-oxides.ÖеÄcomplexesÔõô·Òë Çë¸ßÊÖÖ¸µã |
» ²ÂÄãϲ»¶
085602µ÷¼Á ³õÊÔ×Ü·Ö335
ÒѾÓÐ5È˻ظ´
302·Ö 085601Çóµ÷¼ÁÍÆ¼ö
ÒѾÓÐ8È˻ظ´
ÉúÎïѧ308·ÖÇóµ÷¼Á£¨Ò»Ö¾Ô¸»ª¶«Ê¦´ó£©
ÒѾÓÐ10È˻ظ´
²ÄÁÏר˶(0856) 339·ÖÇóµ÷¼Á
ÒѾÓÐ8È˻ظ´
085410È˹¤ÖÇÄÜ ³õÊÔ316·Ö Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
282Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
070300»¯Ñ§Çóµ÷¼Á
ÒѾÓÐ17È˻ظ´
318Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
308Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
315Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
» ±¾Ö÷ÌâÏà¹Ø¼ÛÖµÌùÍÆ¼ö£¬¶ÔÄúͬÑùÓаïÖú:
ÇóÖú¸ßÈ˰ïæ·ÒëÒ»¸ö¶ÌÓ3¸öµ¥´Ê×é³É£©--volume combustion synthesis
ÒѾÓÐ1È˻ظ´
ÓйØÊ³Æ·Ìí¼Ó¼ÁµÄÓ¢ÎÄ£¬°ÑËõдµ¥´Ê·ÒëÒ»ÏÂ
ÒѾÓÐ1È˻ظ´
·ÒëÒ»¾ä»°,µ¥´ÊÓÐ×¢ÊÍ£¬¾ÍÊǾä×ӽṹ²»Ì«»á°²ÅÅ
ÒѾÓÐ5È˻ظ´
Ò»¸öµ¥´Ê
ÒѾÓÐ11È˻ظ´
°ïæ·ÒëÁ½¸öµ¥´Ê
ÒѾÓÐ2È˻ظ´
ÇóÖúSunblaze..µ¥´Ê·Òë..ÒªÇó·ÒëÖÐÎÄΪ2¸ö×Ö
ÒѾÓÐ8È˻ظ´
Ϊʲôһ¸öµ¥´ÊÓÐÄÇô¶àÒâ˼£¬ÎªÊ²Ã´¼ÇÁ˵¥´ÊÒ²²»»á·Òë
ÒѾÓÐ8È˻ظ´
°ïÎÒ·ÒëһƪÎÄÏ×µÄÌâÄ¿£¬Óв¿·Öµ¥´ÊµÄÒâ˼£¬¹Ø¼ü²»»á´®ÆðÀ´·Òë
ÒѾÓÐ5È˻ظ´
·ÒëÈý¸öÈÕÎĵ¥´Ê
ÒѾÓÐ1È˻ظ´
ÖÐÒëÓ¢ ·ÒëÒ»¸öµ¥´Ê£¡£¡
ÒѾÓÐ11È˻ظ´
ÇóÖúÁ½¸öµ¥´ÊµÄ·Ò룡
ÒѾÓÐ2È˻ظ´
Çó·ÒëËĸöµ¥´Ê~~~Ó¢ÓººÓï
ÒѾÓÐ3È˻ظ´
ÇóÖú3¸öµØÖÊ·½ÃæÓ¢Îĵ¥´Ê
ÒѾÓÐ2È˻ظ´
ÇóÒ»¸öµ¥´ÊµÄÒâ˼
ÒѾÓÐ3È˻ظ´
·ÒëÎå¸öµ¥´Ê×é³ÉµÄÒ»¾ä»°
ÒѾÓÐ5È˻ظ´
ÍõСب123321
ͳæ (СÓÐÃûÆø)
- Ó¦Öú: 16 (СѧÉú)
- ½ð±Ò: 969
- ºì»¨: 6
- Ìû×Ó: 277
- ÔÚÏß: 81.4Сʱ
- ³æºÅ: 2143514
- ×¢²á: 2012-11-23
- ÐÔ±ð: MM
- רҵ: ÌÇÄò²¡
2Â¥2013-07-07 01:01:09
ÍõСب123321
ͳæ (СÓÐÃûÆø)
- Ó¦Öú: 16 (СѧÉú)
- ½ð±Ò: 969
- ºì»¨: 6
- Ìû×Ó: 277
- ÔÚÏß: 81.4Сʱ
- ³æºÅ: 2143514
- ×¢²á: 2012-11-23
- ÐÔ±ð: MM
- רҵ: ÌÇÄò²¡
3Â¥2013-07-07 01:13:04
s0s2005
ľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 82 (³õÖÐÉú)
- ½ð±Ò: 13447.5
- ºì»¨: 2
- Ìû×Ó: 1236
- ÔÚÏß: 84.6Сʱ
- ³æºÅ: 2495809
- ×¢²á: 2013-06-04
- ÐÔ±ð: GG
- רҵ: Ó¦ÓÃÓïÑÔѧ
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
|
µÚÒ»¸öÎÊÌâ improvementºÍÆäËû¼¸¸öform£¬formulation,modeÒ»ÆðµÄ in any dosage form, formulation,improvement or mode of administration£¬ Òò´ËÎÒ²»¾õµÃLZ²»»á·Ò룬 µÚ¶þ¸öÎÊÌâͬÉÏ£¬»¹ÊDz¢ÁеĹØÏµ£¬ ΪºÎLZ¾Í·ÇÒª¿Ù³öimprovementºÍcomplexesÄØ£¿ Èç¹ûÆäËû¶¼Ã»ÎÊÌ⣬ ÕâÁ½¸ö°´µÀÀí¾Í¸üûÓÐÎÊÌ⣬ ÒòΪÕâÁ©´ÊÕâ¾ä×Ó¶¼²»ËãÊÇרҵÊõÓïÁË¡£ LzÔÙÊÔÊÔ£¿ |

4Â¥2013-07-07 13:00:09
hanches
Ìú¸Ëľ³æ (ÕýʽдÊÖ)
obscure nacissus
- Ó¦Öú: 113 (¸ßÖÐÉú)
- ¹ó±ö: 0.299
- ½ð±Ò: 4511.3
- É¢½ð: 579
- ºì»¨: 7
- ɳ·¢: 3
- Ìû×Ó: 485
- ÔÚÏß: 460.6Сʱ
- ³æºÅ: 2208505
- ×¢²á: 2012-12-27
- ÐÔ±ð: GG
- רҵ: ʳƷ¿ÆÑ§»ù´¡
¡¾´ð°¸¡¿Ó¦Öú»ØÌû
¡ï ¡ï ¡ï ¡ï ¡ï
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
cclz110: ½ð±Ò+5 2013-07-07 20:03:54
¸Ðл²ÎÓ룬ӦÖúÖ¸Êý +1
cclz110: ½ð±Ò+5 2013-07-07 20:03:54
|
1¡¢improvement, ÎÒÈÏΪ¿ÉÒÔ×÷ÎªÇ°ÃæËùÖ¸µÄformºÍformulationµÄimprovement, ·Òë³É¡°ÔÚÈκμÁÐÍ¡¢Åä·½¼°Æä¸ÄÁ¼¡± 2¡¢·Òë³É¡°¸´ºÏÎÎÒ¾õµÃûÎÊÌâ°¡£¬»òÐíÒ²ÄÜ·³É¡°ÂçºÏÎ°É~ |

5Â¥2013-07-07 16:51:18














»Ø¸´´ËÂ¥